Analysis of predictive biomarker of Erlotinib to non-small cell lung cancer without EGFR mutation

2016 Fiscal Year Final Research Report

• Project/Area Number: 26430161
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Tumor therapeutics
• Research Institution: Kanazawa University
• Principal Investigator: Sone Takashi 金沢大学, 医薬保健学総合研究科, 特任准教授 (30420334)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: EGFR遺伝子変異陰性 / エルロチニブ / 次世代シークエンス

Outline of Final Research Achievements

We analyzed predictive biomarker of erlotinib to NSCLC patients(pts) who have wild-type EGFR.We utilized tumor tissue from the phase II study to evaluate of erlotinib in advanced NSCLC pts who have wild-type EGFR. C-Met gene amplification (GA) was evaluable in 56 patients and 11 pts showed c-Met GA. Progression free survivals of erlotinib was longer in pts with c-Met GA than those without GA. Next-gene-sequence (NGS) was analyzed in 17 pts using cancer panel of fifteen oncogene (TruSight Tumor 15). TP53 mutation was detected 10 pts among 17 pts. There was no difference in DCR, PFS between pts with TP53 mutation and those without TP53 mutation. In NGS analysis, "low coverage" was frequently observed due to low amount and low quality of DNA.
In our study, we could'nt detect biomarker of efficacy of erlotinib to EGFR-wild pts.In NGS analysis using tinny tissue collected for diagnosis, it is matter to keep quality of DNA.

Free Research Field

肺癌